All times are listed in CEST (Central European Summer Time)

Displaying One Session

View
Hamburg Hall Industry Satellite Symposium

AiCME - Aiming to Minimize the Risk of Recurrence in Early Breast Cancer: Integrating Risk Assessment and Adjuvant Therapies into Practice (ID 37)

Date
Thu, 05.05.2022
Time
12:30 - 13:30
Chairs
Session Type
Industry Satellite Symposium
AiCME - Aiming to Minimize the Risk of Recurrence in Early Breast Cancer: Integrating Risk Assessment and Adjuvant Therapies into Practice (ID 37)

Welcome and Introduction (ID 435)

Lecture Time
12:30 - 12:30
Speakers
Authors
Session Name
AiCME - Aiming to Minimize the Risk of Recurrence in Early Breast Cancer: Integrating Risk Assessment and Adjuvant Therapies into Practice (ID 37)
Room
Hamburg Hall
Date
Thu, 05.05.2022
Time
12:30 - 13:30
AiCME - Aiming to Minimize the Risk of Recurrence in Early Breast Cancer: Integrating Risk Assessment and Adjuvant Therapies into Practice (ID 37)

Predicting Risk of Recurrence in HR-positive, HER2-negative Early Breast Cancer: A Focus on Clinicopathological Factors (ID 436)

Lecture Time
12:30 - 12:30
Speakers
Authors
Session Name
AiCME - Aiming to Minimize the Risk of Recurrence in Early Breast Cancer: Integrating Risk Assessment and Adjuvant Therapies into Practice (ID 37)
Room
Hamburg Hall
Date
Thu, 05.05.2022
Time
12:30 - 13:30
AiCME - Aiming to Minimize the Risk of Recurrence in Early Breast Cancer: Integrating Risk Assessment and Adjuvant Therapies into Practice (ID 37)

Tools to Guide Risk Assessment and Adjuvant Treatment Decisions in HR-positive, HER2-negative Early Breast Cancer: A Focus on Best Practices (ID 437)

Lecture Time
12:30 - 12:30
Speakers
Authors
Session Name
AiCME - Aiming to Minimize the Risk of Recurrence in Early Breast Cancer: Integrating Risk Assessment and Adjuvant Therapies into Practice (ID 37)
Room
Hamburg Hall
Date
Thu, 05.05.2022
Time
12:30 - 13:30
AiCME - Aiming to Minimize the Risk of Recurrence in Early Breast Cancer: Integrating Risk Assessment and Adjuvant Therapies into Practice (ID 37)

Impact of CDK4/6 Inhibitors as Adjuvant Therapy in HR-positive, HER2-negative Early Breast Cancer: A Focus on Recent Evidence (ID 438)

Lecture Time
12:30 - 12:30
Speakers
Authors
Session Name
AiCME - Aiming to Minimize the Risk of Recurrence in Early Breast Cancer: Integrating Risk Assessment and Adjuvant Therapies into Practice (ID 37)
Room
Hamburg Hall
Date
Thu, 05.05.2022
Time
12:30 - 13:30
AiCME - Aiming to Minimize the Risk of Recurrence in Early Breast Cancer: Integrating Risk Assessment and Adjuvant Therapies into Practice (ID 37)

Optimizing the Use of CDK4/6 Inhibitors as Adjuvant Therapy in HR-positive, HER2-negative Early Breast Cancer: A Focus on Patient Management (ID 439)

Lecture Time
12:30 - 12:30
Speakers
Authors
Session Name
AiCME - Aiming to Minimize the Risk of Recurrence in Early Breast Cancer: Integrating Risk Assessment and Adjuvant Therapies into Practice (ID 37)
Room
Hamburg Hall
Date
Thu, 05.05.2022
Time
12:30 - 13:30
AiCME - Aiming to Minimize the Risk of Recurrence in Early Breast Cancer: Integrating Risk Assessment and Adjuvant Therapies into Practice (ID 37)

Questions and Take-Home Learnings (ID 440)

Lecture Time
12:30 - 12:30
Speakers
Authors
Session Name
AiCME - Aiming to Minimize the Risk of Recurrence in Early Breast Cancer: Integrating Risk Assessment and Adjuvant Therapies into Practice (ID 37)
Room
Hamburg Hall
Date
Thu, 05.05.2022
Time
12:30 - 13:30